Tandem Diabetes Care's stock surged 9.64% in after-hours trading following the release of its first-quarter financial results, which showed significant improvement across key metrics.

The medical device company reported Q1 sales of $247.2 million, representing a 5% year-over-year increase, while its net loss narrowed to $20.4 million from wider losses in previous periods. Gross margin climbed 4.8 percentage points to 55%, demonstrating improved operational efficiency.

The company also reported strong operational performance with pump shipments exceeding 29,000 worldwide, including more than 19,000 in the US market. Tandem Diabetes Care reaffirmed its full-year 2026 sales outlook of $1.065 billion to $1.085 billion and projected gross margin of 56%-57%.